8-K filing — PALISADE BIO, INC. (PALI)
Filed: 2026-11-10 AccNo: 0001357459-26-000025 Size: 639 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Palisade Bio announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programs for PALI-2108.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-10 AccNo: 0001357459-26-000025 Size: 639 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Palisade Bio has initiated dosing in its global Phase 2b clinical trial, ASCENTRA-UC, evaluating the efficacy and safety of PALI-2108 in patients with ulcerative colitis.
Palisade Bio presented new translational evidence and data demonstrating rapid endoscopic improvement for its lead product candidate, PALI-2108, at the United European Gastroenterology (UEG) Week 2026.
linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The findings connect
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo presentations selected for